Sarepta Therapeutics (SRPT) Surges as Eteplirsen Met the Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Sarepta (SRPT) to Update on Additional Eteplirsen Phase IIb Data
October 12, 2012 4:09 PM EDTSarepta Therapeutics (NASDAQ: SRPT) announced that data from a Phase IIb study evaluating eteplirsen, an investigational treatment for boys with Duchenne muscular dystrophy (DMD), will be presented Saturday, October 13th at the World Muscle Society in Perth, Australia. Principal investigator, Jerry R. Mendell, M.D. of Nationwide Children's Hospital, will present the data in an oral presentation of the abstract titled, "Results at 48 Weeks of a Phase IIb Extension Study of the... More
Wedbush Lifts Target on Sarepta Therapeutic (SRPT) to $70, Drug Could Sell for $300-$400K/year
October 4, 2012 3:50 PM EDTIn a note late Wednesday, Wedbush substantially raised its price target Outperform-rated Sarepta Therapeutic (NASDAQ: SRPT) from $26 to $70 following positive results from their Phase IIb extension trial of eteplirsen for Duchenne muscular dystrophy.
Some highlights from the report:
"Importantly, boys... More
Sarepta (SRPT) Says Eteplirsen Met Primary Endpoint in Phase IIb
October 3, 2012 7:08 AM EDTSarepta Therapeutics (Nasdaq: SRPT), announced that treatment with its lead exon-skipping compound, eteplirsen, met the primary efficacy endpoint, increase in novel dystrophin, and achieved a significant clinical benefit on the primary clinical outcome, the 6-minute walk test (6MWT) over the placebo/delayed treatment cohort in a Phase IIb extension trial in Duchenne muscular dystrophy (DMD) patients.
... More
Sarepta (SRPT) Receives Termination Notice from U.S. DoD for Ebola Program
October 3, 2012 7:07 AM EDTSarepta Therapeutics, Inc. (Nasdaq: SRPT) received notice from the U.S. Department of Defense (DoD) that the Ebola portion of the Company's contract for the advanced development of hemorrhagic fever virus therapeutics was terminated for the convenience of the government due to funding constraints. The DoD's Joint Project Manager Transformational Medical Technologies (JPM-TMT) awarded this contract in July 2010 to advance a platform... More
After-Hours Movers 10/02: (ITMN) (FIRE) (MUR) Higher; (XRTX) (ATRS) (CLWR) Lower (more...)
October 2, 2012 5:02 PM EDTXyratex, Ltd. (NASDAQ: XRTX) 13% LOWER; Misses Q3 EPS by 7c; Sees Potential Q4 Loss
Antares Pharma (NASDAQ: ATRS) 9% LOWER;... More
Sarepta Therapeutics (SRPT) Moves Up Ahead of Call to Discuss 48-Week Results From the Phase IIb DMD Study
October 2, 2012 4:33 PM EDTRecent momentum mover Sarepta Therapeutics (NASDAQ: SRPT) is moving higher after-hours Tuesday after the company announced that will hold a conference call at 8:00 a.m. EDT on Wednesday, October 3, 2012 to discuss 48-week results from its Phase IIb study evaluating eteplirsen for the treatment of Duchenne... More
